Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

[1]  C. Paweletz,et al.  EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd , 2021, Cancer Research.

[2]  Ye Zhang,et al.  NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells , 2021, Cells.

[3]  Yu Seong Lee,et al.  STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer , 2021, Journal for ImmunoTherapy of Cancer.

[4]  B. Zhu,et al.  Mechanism underlying resveratrol's attenuation of paclitaxel cytotoxicity in human breast cancer cells: Role of the SIRT1-FOXO1-HER3 signaling pathway. , 2021, Cancer treatment and research communications.

[5]  Luke H. Hoeppner,et al.  DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma , 2021, bioRxiv.

[6]  Ying Cheng,et al.  Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study , 2021, Targeted Oncology.

[7]  M. Pina,et al.  Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer , 2020, Cureus.

[8]  R. Cheng,et al.  Cardio-Oncology Education and Training: JACC Council Perspectives. , 2020, Journal of the American College of Cardiology.

[9]  K. Brindle,et al.  Breast cancer–associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells , 2020, Science Signaling.

[10]  D. Shaw,et al.  Structural basis of AZD9291 selectivity for EGFR T790M. , 2020, Journal of medicinal chemistry.

[11]  Alex J. Pollock,et al.  A STING-based biosensor affords broad cyclic dinucleotide detection within single living eukaryotic cells , 2020, Nature Communications.

[12]  H. Blons,et al.  High expression of spliced X-Box Binding Protein 1 in lung tumors is associated with cancer aggressiveness and epithelial-to-mesenchymal transition , 2020, Scientific Reports.

[13]  Sanjeev Gupta,et al.  Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges. , 2020, Cancer letters.

[14]  S. Ameer-Beg,et al.  Adaptive optics for a time-resolved Förster resonance energy transfer (FRET) and fluorescence lifetime imaging microscopy (FLIM) in vivo , 2020, Optics letters.

[15]  S. Iacobelli,et al.  HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies , 2020, EMBO molecular medicine.

[16]  Z. Modrušan,et al.  Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. , 2020, Immunity.

[17]  K. Politi,et al.  Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations , 2020, Cancer Research.

[18]  M. Ahn,et al.  TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  L. Zitvogel,et al.  Trial watch: STING agonists in cancer therapy , 2020, Oncoimmunology.

[20]  Fei Guo,et al.  PKR-dependent cytosolic cGAS foci are necessary for intracellular DNA sensing , 2019, Science Signaling.

[21]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[22]  A. Barac,et al.  Trastuzumab-Induced Cardiomyopathy. , 2019, Cardiology clinics.

[23]  M. van den Broek,et al.  Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity. , 2019, Cell reports.

[24]  R. Medzhitov,et al.  Harnessing innate immunity in cancer therapy , 2019, Nature.

[25]  E. Giovannetti,et al.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.

[26]  X. Che,et al.  M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer , 2019, Cancer management and research.

[27]  M. Westphal,et al.  EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients , 2019, Scientific Reports.

[28]  Cheryl Gillet,et al.  Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast Cancer , 2019, Cell reports.

[29]  Sandra Healy,et al.  The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistance , 2018, Biology of the cell.

[30]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.

[31]  K. Nishio,et al.  An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC , 2018, Oncogene.

[32]  R. Vance,et al.  Tumor‐Derived cGAMP Triggers a STING‐Mediated Interferon Response in Non‐tumor Cells to Activate the NK Cell Response , 2018, Immunity.

[33]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[34]  Samuel F. Bakhoum,et al.  Chromosomal instability drives metastasis through a cytosolic DNA response , 2017, Nature.

[35]  T. Salame,et al.  An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors , 2017, EMBO molecular medicine.

[36]  D. Rimm,et al.  Worldwide Frequency of Commonly Detected EGFR Mutations. , 2017, Archives of pathology & laboratory medicine.

[37]  D. Gomez-Nicola,et al.  STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. , 2017, Cancer research.

[38]  V. Gebski,et al.  Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival , 2017, Journal of the National Cancer Institute.

[39]  Juan R. Cubillos-Ruiz,et al.  Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer , 2017, Cell.

[40]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[41]  Jeremy J. W. Chen,et al.  Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients , 2016, Oncotarget.

[42]  A. Bardelli,et al.  The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death , 2016, Nature Medicine.

[43]  C. Hetz,et al.  Endoplasmic Reticulum Stress and the Hallmarks of Cancer. , 2016, Trends in cancer.

[44]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[45]  G. Sala,et al.  HER-3: hub for escape mechanisms , 2015, Aging.

[46]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[47]  J. Ravetch,et al.  Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions , 2015, Cancer Immunology Research.

[48]  R. Jordan,et al.  Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages , 2015, The Journal of Immunology.

[49]  J. Ravetch,et al.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect , 2015, Cell.

[50]  J. Vicencio,et al.  Plasma exosomes protect the myocardium from ischemia-reperfusion injury. , 2015, Journal of the American College of Cardiology.

[51]  Bonnie L Boster,et al.  Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[52]  Y. Yarden,et al.  Examination of HER3 targeting in cancer using monoclonal antibodies , 2015, Proceedings of the National Academy of Sciences.

[53]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[54]  N. Tinari,et al.  EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. , 2013, Translational oncology.

[55]  Jonathan L. Schmid-Burgk,et al.  Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP , 2013, Nature.

[56]  J. Ravetch,et al.  Mouse model recapitulating human Fcγ receptor structural and functional diversity , 2012, Proceedings of the National Academy of Sciences.

[57]  N. Tinari,et al.  An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling , 2012, Oncogene.

[58]  D. Noonan,et al.  Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. , 2011, Future cardiology.

[59]  William Pao,et al.  Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase , 2011, Proceedings of the National Academy of Sciences.

[60]  R A Knight,et al.  Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes , 2009, Cell Death and Differentiation.

[61]  S. Ameer-Beg,et al.  Multiphoton time-domain fluorescence lifetime imaging microscopy: practical application to protein–protein interactions using global analysis , 2009, Journal of the Royal Society Interface.

[62]  P. Sugden,et al.  ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. , 2008, Journal of molecular and cellular cardiology.

[63]  K. Carraway,et al.  Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. , 2008, Cancer research.

[64]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[65]  Marion Peter,et al.  Imaging molecular interactions by multiphoton FLIM , 2004, Biology of the cell.

[66]  A. Papaioannou,et al.  Driving Cancer Tumorigenesis and Metastasis Through UPR Signaling. , 2018, Current topics in microbiology and immunology.

[67]  A. Lux,et al.  Of Mice and Men: The Need for Humanized Mouse Models to Study Human IgG Activity in Vivo , 2012, Journal of Clinical Immunology.

[68]  S. Kobayashi,et al.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.

[69]  L. Liu,et al.  The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. , 2011, Neoplasma.

[70]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[71]  J. Ravetch,et al.  Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.